Celcuity Inc. (NASDAQ:CELC) Short Interest Down 8.0% in August

Celcuity Inc. (NASDAQ:CELC) was the target of a large decline in short interest during the month of August. As of August 31st, there was short interest totalling 2,290,000 shares, a decline of 8.0% from the August 15th total of 2,490,000 shares. Based on an average trading volume of 370,300 shares, the short-interest ratio is presently 6.2 days.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. HC Wainwright reissued a “buy” rating and set a $27.00 price target on shares of Celcuity in a research note on Thursday, August 15th. Lifesci Capital started coverage on shares of Celcuity in a report on Monday, August 26th. They set an “outperform” rating and a $27.00 target price on the stock. Leerink Partners initiated coverage on shares of Celcuity in a research note on Monday, July 22nd. They set an “outperform” rating and a $29.00 price target for the company. Leerink Partnrs upgraded shares of Celcuity to a “strong-buy” rating in a report on Monday, July 22nd. Finally, Stifel Nicolaus decreased their price objective on Celcuity from $40.00 to $39.00 and set a “buy” rating for the company in a report on Thursday, August 15th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $28.67.

Celcuity Price Performance

Shares of NASDAQ CELC opened at $15.01 on Thursday. The company has a market capitalization of $526.87 million, a PE ratio of -5.40 and a beta of 0.76. The company has a quick ratio of 14.95, a current ratio of 14.95 and a debt-to-equity ratio of 0.54. Celcuity has a twelve month low of $8.39 and a twelve month high of $22.19. The firm has a fifty day simple moving average of $16.76 and a 200 day simple moving average of $16.94.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.09. During the same period last year, the company earned ($0.66) earnings per share. On average, sell-side analysts forecast that Celcuity will post -2.54 EPS for the current year.

Hedge Funds Weigh In On Celcuity

A number of institutional investors and hedge funds have recently modified their holdings of CELC. Perceptive Advisors LLC acquired a new position in shares of Celcuity during the 4th quarter valued at $21,583,000. Commodore Capital LP raised its holdings in shares of Celcuity by 3.6% during the fourth quarter. Commodore Capital LP now owns 1,754,704 shares of the company’s stock valued at $25,566,000 after purchasing an additional 60,563 shares during the period. Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Celcuity during the 1st quarter worth about $3,545,000. Hennion & Walsh Asset Management Inc. acquired a new stake in shares of Celcuity in the 2nd quarter valued at about $888,000. Finally, Vanguard Group Inc. increased its position in Celcuity by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 828,597 shares of the company’s stock valued at $17,898,000 after buying an additional 7,821 shares in the last quarter. 63.33% of the stock is currently owned by institutional investors.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.